Arvinas (ARVN) Research & Development (2017 - 2026)
Arvinas (ARVN) posted quarterly Research & Development of $60.3 million for Q1 2026, down 33.59% year-over-year from $90.8 million in Q1 2025, and down 1.31% quarter-over-quarter from $61.1 million in Q4 2025.
Arvinas (ARVN) Research & Development (2017 - 2026) Analysis & Trends
Arvinas' Research & Development history runs 10 years deep, the most recent figure standing at $60.3 million for Q1 2026.
- In Q1 2026, Research & Development fell 33.59% year-over-year to $60.3 million; the TTM figure through Mar 2026 stood at $254.7 million (down 28.19% YoY), while the FY2025 annual figure was $285.2 million, down 18.09% from the prior year.
- Research & Development for Q1 2026 stood at $60.3 million, down from $61.1 million in the prior quarter.
- The five-year high for Research & Development was $103.4 million in Q2 2023, with the low at $60.3 million in Q1 2026.
- The 5-year median for Research & Development is $84.3 million (2024), against an average of $81.7 million.
- The sharpest annual moves came in 2022 and 2026: Research & Development jumped 90.89% in 2022, then tumbled 33.59% in 2026.
- Arvinas' Research & Development stood at $98.3 million in 2022, then declined by 3.15% to $95.2 million in 2023, then slipped by 12.5% to $83.3 million in 2024, then decreased by 26.65% to $61.1 million in 2025, then fell by 1.31% to $60.3 million in 2026.
- Business Quant data shows ARVN's Research & Development at $60.3 million in Q1 2026, $61.1 million in Q4 2025, and $64.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 52.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.60 Mn |
| Mar 31, 2026 | 60.30 Mn |
| Dec 31, 2025 | 61.10 Mn |
| Sep 30, 2025 | 64.70 Mn |
| Jun 30, 2025 | 68.60 Mn |
| Mar 31, 2025 | 90.80 Mn |
| Dec 31, 2024 | 83.30 Mn |
| Sep 30, 2024 | 86.90 Mn |
| Jun 30, 2024 | 93.70 Mn |
| Mar 31, 2024 | 84.30 Mn |
| Dec 31, 2023 | 95.20 Mn |
| Sep 30, 2023 | 85.90 Mn |
| Jun 30, 2023 | 103.40 Mn |
| Mar 31, 2023 | 95.30 Mn |
| Dec 31, 2022 | 98.30 Mn |
| Sep 30, 2022 | 77.50 Mn |
| Jun 30, 2022 | 75.30 Mn |
| Mar 31, 2022 | 64.00 Mn |
| Dec 31, 2021 | 61.90 Mn |
| Sep 30, 2021 | 40.60 Mn |